Ovarian cancer trials in Germany
45 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 Nov 2026. Ask the study team whether a trial fits you.
Phase 3RecruitingTrial-stage medicine
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
- Where
- Berlin, Bonn, Dresden, Düsseldorf, Tübingen
- Age
- 18 years and over
- People
- 420 worldwide
- Run by
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT07546500Registry updated 2026-11-09
Phase 3RecruitingTrial-stage medicine
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
- Where
- Berlin, Bonn, Düsseldorf, Hanover, Wiesbaden
- Age
- 18 years and over
- People
- 950 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07851025EU 2026-526895-22-00Registry updated 2026-11-06
Phase 1RecruitingTrial-stage medicine
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Where
- Essen
- Age
- 18 years and over
- People
- 340 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213791EU 2025-521887-37-00Registry updated 2026-11-04
Phase 3RecruitingTrial-stage medicine
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Where
- Aachen, Berlin, Bonn, Cologne, Dresden, Düsseldorf, Erlangen, Essen, Kiel, Ulm
- Age
- 18 years and over
- People
- 1,630 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213804EU 2025-522255-25-00Registry updated 2026-11-04
Phase 3RecruitingTrial-stage medicine
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
- Where
- Berlin, Bonn, Dresden, Duesseldorf, Erlangen, Essen, Frankfurt Am Main, Freiburg im Breisgau, Homburg, Magdeburg
- Age
- 18 years and over
- People
- 688 worldwide
- Run by
- Genmab
See details and how to joinNCT07564141EU 2025-524202-15-00Registry updated 2026-11-04
Phase 1/2RecruitingTrial-stage medicine
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Where
- Berlin, Cologne, Dresden, Heidelberg
- Age
- 18 years and over
- People
- 334 worldwide
- Run by
- Gilead Sciences
See details and how to joinNCT06303505EU 2024-511074-80-01Registry updated 2026-11-03
Phase 3RecruitingTrial-stage medicine
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
- Where
- Berlin, Dresden, Essen, Frankfurt am Main, Hamburg, Mannheim, Ulm
- Age
- 18 years and over
- People
- 270 worldwide
- Run by
- Verastem, Inc.
See details and how to joinNCT06072781EU 2023-508204-38-00Registry updated 2026-11-02
Phase 3RecruitingResearch participation
Phase 3 Study of Azenosertib Versus Chemotherapy in Platinum-Resistant Ovarian Cancers Positive for Cyclin E1 Protein Expression
- Where
- Berlin, Dresden
- Age
- 18 years and over
- People
- 197 worldwide
- Run by
- K-Group Beta Inc.
See details and how to join2025-524641-27-00EU 2025-524641-27-00Registry updated 2026-10-30
Phase 2RecruitingTrial-stage medicine
WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC
- Where
- Berlin, Dresden, Essen, Hamburg, Mannheim, Munich
- Age
- 18 years and over
- People
- 60
- Run by
- AGO Research GmbH
See details and how to joinNCT04644289EU 2024-511780-28-00Registry updated 2026-10-30
Phase 2RecruitingTrial-stage medicine
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- Where
- Frankfurt am Main, Giessen
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT06953089EU 2025-523895-22-00Registry updated 2026-10-29
Phase 3RecruitingTrial-stage medicine
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Where
- Berlin, Bonn, Detmold, Dresden, Essen, Hamburg, Heilbronn, Jena, Leipzig, Ludwigsburg, Mannheim, Marburg, Muenster, Munich, Regensburg, Schwaebisch Hall, Ulm, Wiesbaden
- Age
- 18 years and over
- People
- 582 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06819007EU 2024-516982-35-00Registry updated 2026-10-28
Phase 2/3RecruitingTrial-stage medicine
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Where
- Dresden, Essen, Hamburg, Mannheim, Ulm
- Age
- 18 years and over
- People
- 860 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06161025EU 2023-507914-28-00Registry updated 2026-10-26
Phase 2RecruitingTrial-stage medicine
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Frankfurt
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478EU 2023-507641-29-00Registry updated 2026-10-26
Phase 1/2RecruitingTrial-stage medicine
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Berlin, Dresden, Heidelberg, Heilbronn, Leipzig, Mainz, Muenster
- Age
- 18 years and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064EU 2023-509632-26-00Registry updated 2026-10-26
Phase 2RecruitingTrial-stage medicine
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
- Where
- Aachen, Baden-Baden, Berlin, Bonn, Cologne, Detmold, Dortmund, Dresden, Duesseldorf, Essen, Freiburg im Breisgau, Goettingen, Hamburg, Jena, Kiel, Leipzig, Munich, Schwaebisch Hall, Unna, Wiesbaden
- Age
- 18 years and over
- People
- 640 worldwide
- Run by
- North Eastern German Society of Gynaecological Oncology
See details and how to joinNCT05460000EU 2022-502559-69-01Registry updated 2026-10-23
Phase 3RecruitingTrial-stage medicine
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
- Where
- Bad Homburg, Bonn, Brandenburg, Dresden, Düsseldorf, Essen, Gütersloh, Halle, Hamburg, Homburg, Kassel, Mainz, Mannheim, Münster, Schweinfurt, Wiesbaden, Wuppertal
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07816666EU 2026-526776-23-00Registry updated 2026-10-16
Phase 1/2RecruitingTrial-stage medicine
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
- Where
- Bochum, München, Ulm
- Age
- 18 years and over
- People
- 245 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07186842EU 2025-522613-26-00Registry updated 2026-10-15
Phase 3RecruitingTrial-stage medicine
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Where
- Bonn, Dresden, Kassel, Kiel, Mannheim, Minden, Tuebingen
- Age
- 18 years and over
- People
- 466 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07214779EU 2025-522748-42-00Registry updated 2026-10-15
Phase 3RecruitingTrial-stage medicine
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Where
- Aachen, Berlin, Detmold, Dresden, Jena, Kassel, Leipzig
- Age
- 18 years and over
- People
- 900 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07318558EU 2023-508047-40-00Registry updated 2026-10-13
Phase 3RecruitingTrial-stage medicine
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
- Where
- Dresden, Essen, Gütersloh, Hamburg, Heilbronn, Kassel, Limburg, Mainz, Muenster, Schwaebisch Hall, Stuttgart
- Age
- 18 years and over
- People
- 544 worldwide
- Run by
- Genmab
See details and how to joinNCT07225270EU 2025-522167-15-00Registry updated 2026-10-06
Phase 1/2RecruitingTrial-stage medicine
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Where
- Bayern, Berlin, Heidelberg, Mainz
- Age
- 18 years to 130 years
- People
- 695 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05417594EU 2023-504984-17-00Registry updated 2026-10-05
Phase 1/2RecruitingTrial-stage medicine
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Where
- Berlin, Essen, Freiburg im Breisgau, Hanover, Leipzig, Mannheim, Regensburg
- Age
- 18 years to 130 years
- People
- 622 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05797168EU 2022-502576-23-00Registry updated 2026-10-05
Phase 1/2RecruitingTrial-stage medicine
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- Augsburg, Essen, Frankfurt am Main, Hamburg, Heidelberg
- Age
- 12 years and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750Registry updated 2026-10-02
Phase 2RecruitingTrial-stage medicine
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Where
- Berlin, Essen, Hanover, München, Regensburg
- Age
- 18 years to 130 years
- People
- 454 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05489211EU 2023-509436-26-00Registry updated 2026-09-23
Phase 1/2RecruitingTrial-stage medicine
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Where
- Cologne, Esslingen am Neckar, Moers, Nuremberg
- Age
- 18 years and over
- People
- 534 worldwide
- Run by
- Revolution Medicines, Inc.
See details and how to joinNCT06128551Registry updated 2026-09-22
All Ovarian cancer trials and the map
This page is not medical advice. Talk to your doctor before contacting a trial.